BioNxt Solutions Inc. (CVE:BNXT) | WebDisclosure

Basculer en Français

9546	Companies
188159	Keywords
120049	Articles
100505	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

BRIEF

published on 12/17/2025 at 09:10, 14 hours 29 minutes ago

BioNxt fait des progrès dans le domaine des médicaments à dissolution rapide

Maladies Auto-immunes Administration De Médicaments Technologie Des Couches Minces Protection Par Brevet Dysphagie
BRIEF

published on 12/17/2025 at 09:10, 14 hours 29 minutes ago

BioNxt Advances with Rapid-Dissolving Drug Technology

Autoimmune Diseases Drug Delivery Patent Protection Thin-film Technology Dysphagia
PRESS RELEASE

published on 12/17/2025 at 09:05, 14 hours 34 minutes ago

Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies
BioNxt Solutions Inc. announces breakthrough in drug delivery for dysphagia, securing first national-level patent for thin-film platform, targeting autoimmune markets with bioequivalent cladribine treatment

BioNxt Solutions Inc. Drug Delivery Dysphagia Thin-film Platform Autoimmune Markets
BRIEF

published on 12/09/2025 at 09:10, 8 days 14 hours ago

BioNxt Develops "Melt in Your Mouth" Cladribine for MS Patients

Multiple Sclerosis Cladribine BioNxt Solutions Melt In Your Mouth Drug-delivery
BRIEF

published on 12/09/2025 at 09:10, 8 days 14 hours ago

BioNxt développe une cladribine « fondante » pour les patients atteints de SEP.

Sclérose En Plaques Cladribine Solutions BioNxt Administration De Médicaments Fond Dans La Bouche
PRESS RELEASE

published on 12/09/2025 at 09:05, 8 days 14 hours ago

BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia
BioNxt Solutions Inc. is developing a sublingual cladribine ODF to enhance MS treatment access. The innovative technology aims to improve swallowing difficulties and increase therapy adherence

BioNxt Solutions Inc. Multiple Sclerosis Drug Delivery Cladribine ODF Melt In Your Mouth
BRIEF

published on 12/01/2025 at 09:10, 16 days 14 hours ago

BioNxt Solutions to Acquire IP for Sublingual Chemotherapy Drug

Intellectual Property Chemotherapy BioNxt Solutions Sublingual Drug Immunosuppressant Market
BRIEF

published on 12/01/2025 at 09:10, 16 days 14 hours ago

BioNxt Solutions va acquérir la propriété intellectuelle d'un médicament de chimiothérapie sublinguale

Propriété Intellectuelle Chimiothérapie Solutions BioNxt Médicament Sublingual Marché Des Immunosuppresseurs
PRESS RELEASE

published on 12/01/2025 at 09:05, 16 days 14 hours ago

BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments
BioNxt Solutions collaborates with European chemotherapy company for novel sublingual drug formulation with high-potency ingredient. Focus on oncology and immunosuppressant treatments. Company plans to expand IP portfolio

Oncology BioNxt Solutions European Chemotherapy Company Sublingual Drug Formulation Immunosuppressant
BRIEF

published on 11/20/2025 at 09:10, 27 days 14 hours ago

BioNxt Receives Eurasian Patent for Sublingual Cladribine Platform

Global Market Autoimmune Diseases Patent Grant BioNxt Solutions Sublingual Cladribine

Accesswire

Published on 12/17/2025 at 23:15, 24 minutes ago

Northern Superior Announces the Ratio for the Distribution of the Common Shares in the Capital of ONGold Resources Ltd.
Published on 12/17/2025 at 15:00, 8 hours 39 minutes ago

BlackBerry Unveils Ground-Up Modernization of BlackBerry AtHoc Mobile Experience to Enable More Intelligent Operations
Published on 12/17/2025 at 14:00, 9 hours 39 minutes ago

UniDoc Completes H3 Health Cube Installation in Italy
Published on 12/17/2025 at 13:35, 10 hours 4 minutes ago

Silver X Mining Announces Grant of Incentive Stock Options and Restricted Share Units
Published on 12/17/2025 at 13:15, 10 hours 24 minutes ago

Aclara Wins UN Global Compact Award for Its Contribution to Local Employment and Suppliers

View all ACCESSWIRE

EQS Group

Published on 12/17/2025 at 22:05, 1 hour 34 minutes ago

Abivax annonce l’acceptation de 22 abstracts sur obefazimod dans les MICI à l’ECCO 2026, dont une présentation orale sur des résultats précliniques antifibrotiques
Published on 12/17/2025 at 22:05, 1 hour 34 minutes ago

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
Published on 12/17/2025 at 21:22, 2 hours 17 minutes ago

EQS-Adhoc: DATAGROUP SE: DATAGROUP SE Management Board plans dividend of EUR 0.04 per share
Published on 12/17/2025 at 20:12, 3 hours 27 minutes ago

EQS-Adhoc: Rheinmetall AG: Executive Board decides to sell activities of the civil division Power Systems – Target is sale in the first quarter of 2026; update of outlook for continuing operation
Published on 12/17/2025 at 19:39, 3 hours 59 minutes ago

Avolta awarded Shanghai Pudong International Airport concession, marking a first-in-a-generation duty-free win for an international operator in mainland China

Les Echos

Published on 12/17/2025 at 20:39, 3 hours ago

Aeroports de Paris SA | 2026 Airport charges in Paris
Published on 12/17/2025 at 20:39, 3 hours ago

Aeroports de Paris SA | Tarifs des redevances aeroportuaires 2026 à Paris
Published on 12/17/2025 at 19:30, 4 hours 9 minutes ago

Change in the composition of the Board
Published on 12/17/2025 at 19:30, 4 hours 9 minutes ago

Evolution de la composition du Conseil d’Administration
Published on 12/17/2025 at 18:00, 5 hours 39 minutes ago

Outstanding Shares and Voting Rights Statement at 30 November 2025

View all LES ECHOS COMFI WIRE